About Us
Hutchison China MediTech Limited, known as Chi-Med, is an innovative biopharmaceutical company aiming to become a global leader in the discovery, development and commercialisation of targeted therapies and immunotherapies in oncology and autoimmune diseases.

Our Innovation Platform, known as Hutchison MediPharma, has been the main driver of creating and developing our portfolio of drug candidates since 2002. It has about 500 scientists and staff focusing on discovering, developing and commercializing targeted therapeutics and immunotherapies in oncology and autoimmune diseases.  It has a portfolio of eight cancer drug candidates currently in clinical studies around the world. 

We have also developed a profitable Commercial Platform, which manufactures, markets and distributes prescription drugs and consumer health products in China.

Chi-Med is listed on the London Stock Exchange’s AIM market and on the Nasdaq Global Select Market (AIM/Nasdaq: HCM).